$APTO
Aptose Biosciences Inc. Stock $apto

$apto Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000117184319005214 Filed on August 06, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.250M	$2.810M	$2.500M
YoY Change	12.5%	12.4%	81.16%
% of Gross Profit
Research & Development	$4.751M	$3.491M	$7.818M
YoY Change	32.3%	-55.35%	618.57%
% of Gross Profit
Depreciation & Amortization	$33.00K	$53.00K	$19.00K
YoY Change	13.79%	178.95%	-17.39%
% of Gross Profit
Operating Expenses	$7.027M	$6.346M	$10.33M
YoY Change	25.24%	-38.56%	316.32%
Operating Profit
YoY Change
Interest Expense	$180.0K	$130.0K	$70.00K
YoY Change	125.0%	85.71%	75.0%
% of Operating Profit
Other Income/Expense, Net	$183.0K	$128.0K	$67.00K
YoY Change	128.75%	91.04%	67.5%
Pretax Income	-$6.840M	-$6.220M	-$10.26M
YoY Change	23.69%	-39.38%	320.49%
Income Tax
% Of Pretax Income
Net Earnings	-$6.844M	-$6.218M	-$10.26M
YoY Change	23.74%	-39.41%	320.4%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$123.4K	-$133.8K	-$302.2K
COMMON SHARES
Basic Shares Outstanding	55.45M	43.76M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$30.20M	$35.40M	$18.50M
YoY Change	93.59%	91.35%	69.72%
Cash & Equivalents	$20.69M	$26.90M	$17.94M
Short-Term Investments	$9.500M	$8.500M	$500.0K
Other Short-Term Assets	$109.0K	$168.0K	$205.0K
YoY Change	-21.58%	-18.05%	2.5%
Inventory
Prepaid Expenses	$285.0K	$722.0K	$388.0K
Receivables
Other Receivables
Total Short-Term Assets	$30.61M	$36.27M	$19.06M
YoY Change	90.53%	90.3%	70.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$361.0K	$352.0K	$231.0K
YoY Change	56.96%	52.38%	15.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.852M	$1.925M	$231.0K
YoY Change	705.22%	733.33%	131.0%
TOTAL ASSETS
Total Short-Term Assets	$30.61M	$36.27M	$19.06M
Total Long-Term Assets	$1.852M	$1.925M	$231.0K
Total Assets	$32.46M	$38.19M	$19.29M
YoY Change	99.2%	98.0%	70.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.174M	$1.240M	$1.146M
YoY Change	-1.1%	8.2%	14.6%
Accrued Expenses	$2.221M	$1.486M	$1.255M
YoY Change	87.74%	18.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$500.0K	$500.0K
YoY Change
Total Short-Term Liabilities	$3.908M	$3.219M	$2.401M
YoY Change	64.89%	34.07%	140.1%
LONG-TERM LIABILITIES
Long-Term Debt	$1.100M	$1.200M	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$1.100M	$1.200M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.908M	$3.219M	$2.401M
Total Long-Term Liabilities	$1.100M	$1.200M	$0.00
Total Liabilities	$5.032M	$4.434M	$2.400M
YoY Change	109.67%	84.75%	140.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$294.2M	-$287.4M	-$263.9M
YoY Change	9.22%	8.9%
Common Stock	$291.3M	$291.2M	$253.1M
YoY Change	14.38%	15.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$27.43M	$33.76M	$16.89M
YoY Change
Total Liabilities & Shareholders Equity	$32.46M	$38.19M	$19.29M
YoY Change	99.2%	98.0%	70.69%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$6.844M	-$6.218M	-$10.26M
YoY Change	23.74%	-39.41%	320.4%
Depreciation, Depletion And Amortization	$33.00K	$53.00K	$19.00K
YoY Change	13.79%	178.95%	-17.39%
Cash From Operating Activities	-$5.184M	-$5.269M	-$9.183M
YoY Change	16.03%	-42.62%	249.3%
INVESTING ACTIVITIES
Capital Expenditures	$42.00K	$26.00K	$100.0K
YoY Change	50.0%	-74.0%
Acquisitions
YoY Change
Other Investing Activities	-$1.000M	-$8.000M	$250.0K
YoY Change		-3300.0%	-108.39%
Cash From Investing Activities	-$1.042M	-$8.026M	$150.0K
YoY Change	3621.43%	-5450.67%	-105.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	17.00K	23.61M	11.57M
YoY Change	-98.94%	104.11%	155.5%
NET CHANGE
Cash From Operating Activities	-5.184M	-5.269M	-9.183M
Cash From Investing Activities	-1.042M	-8.026M	150.0K
Cash From Financing Activities	17.00K	23.61M	11.57M
Net Change In Cash	-6.212M	10.32M	2.536M
YoY Change	115.1%	306.82%	-339.92%
FREE CASH FLOW
Cash From Operating Activities	-$5.184M	-$5.269M	-$9.183M
Capital Expenditures	$42.00K	$26.00K	$100.0K
Free Cash Flow	-$5.226M	-$5.295M	-$9.283M
YoY Change	16.24%	-42.96%	253.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q2	apto	Amortization Of Rightof Use Assets AmortizationOfRightofUseAssets	231000
CY2019Q2	apto	Interest Accrued On Investments InterestAccruedOnInvestments	19000
CY2018Q2	apto	Interest Accrued On Investments InterestAccruedOnInvestments
	apto	Interest Accrued On Investments InterestAccruedOnInvestments	19000
	apto	Interest Accrued On Investments InterestAccruedOnInvestments
	dei	Entity Central Index Key EntityCentralIndexKey	0000882361
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Aptose Biosciences Inc.
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55446564
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	apto
CY2019Q2	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities	23000
CY2018Q2	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities
	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities	47000
	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities
CY2019Q2	apto	Operating Lease Right Of Use Asset Gross OperatingLeaseRightOfUseAssetGross	1804000
CY2019Q2	apto	Research And Development Liabilities Current ResearchAndDevelopmentLiabilitiesCurrent	464000
CY2018Q4	apto	Research And Development Liabilities Current ResearchAndDevelopmentLiabilitiesCurrent	257000
CY2019Q2	apto	Sharebased Compensation Arrangement By Sharebased Payment Award Maximum Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares	9700000
CY2019Q2	apto	Sharebased Compensation Arrangement By Sharebased Payment Award Maximum Subscription Rate SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumSubscriptionRate	0.175
CY2019Q2	apto	Time Deposits Gross TimeDepositsGross	8459000
CY2018Q4	apto	Time Deposits Gross TimeDepositsGross	458000
CY2019Q2	apto	Time Deposits Unrealized Loss TimeDepositsUnrealizedLoss	-18000
CY2018Q4	apto	Time Deposits Unrealized Loss TimeDepositsUnrealizedLoss	18000
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1240000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1315000
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1486000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1474000
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4298000
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4316000
CY2019Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	34178000
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	32963000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1230000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2743000
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	568000
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	515000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1230000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2743000
CY2019Q2	us-gaap	Assets Assets	38190000
CY2018Q4	us-gaap	Assets Assets	16870000
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55435937
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38161808
CY2019Q2	us-gaap	Assets Current AssetsCurrent	36265000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.939
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	291238000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	261072000
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6209000
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16581000
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15408000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15299000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10631000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26898000
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17944000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10317000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	16486000
CY2019Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	1925000
CY2018Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	384000
CY2019Q2	us-gaap	Cash Cash	327000
CY2018Q4	us-gaap	Cash Cash	621000
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26898000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15299000
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2536000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11599000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7313000
CY2019Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	26571000
CY2018Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	14678000
CY2019Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2018Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2018	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55435937
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38161808
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10266000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11706000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17082000
CY2019Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2100000
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top"><td style="width: 0.5in"></td> <td style="width: 0.25in"><div style="display: inline; color: #010000">(f)</div></td> <td style="text-align: justify">Concentration of risk:</td> </tr> </table> <div style=" margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"> </div> <div style=" margin: 0pt 0 0pt 0.75in; font-size: 10pt; text-align: justify; text-indent: 0in">The Company is subject to credit risk from the Company’s cash and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">R1</div>-low or A-low investments and the Company invests only in highly rated Canadian corporations which are capable of prompt liquidation.</div></div></div></div></div>
CY2019Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	53000
CY2018Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	82000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	35000
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2019Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1000
CY2018Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	1000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents
CY2019Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	786000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	955000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y248D
CY2019Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1000
CY2018Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	4000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	3000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-22000
CY2019Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized
CY2018Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-7000
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	2000
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-23000
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2855000
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2511000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5115000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6213000
CY2019Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	70000
CY2018Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	784000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-75000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	557000
CY2019Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	164000
CY2018Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-588000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	90000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	79000
CY2019Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	73000
CY2018Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	108000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	67000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	131000
CY2019Q2	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	183000
CY2018Q2	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	139000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	76000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	66000
CY2019Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	128000
CY2018Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	74000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	220000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	118000
CY2019Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	360000
CY2018Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	600000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	360000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	600000
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1878000
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	119000
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	460000
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	532000
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	521000
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	246000
CY2019Q2	us-gaap	Liabilities Liabilities	4434000
CY2018Q4	us-gaap	Liabilities Liabilities	2789000
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38190000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16870000
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3219000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2789000
CY2019Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23613000
CY2018Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11569000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29791000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20424000
CY2019Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8026000
CY2018Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	150000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8050000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	126000
CY2019Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5269000
CY2018Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9183000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10143000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13237000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-6218000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-10262000
	us-gaap	Net Income Loss NetIncomeLoss	-11724000
	us-gaap	Net Income Loss NetIncomeLoss	-17076000
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	128000
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	67000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	222000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	95000
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	6346000
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	10329000
	us-gaap	Operating Expenses OperatingExpenses	11946000
	us-gaap	Operating Expenses OperatingExpenses	17171000
	us-gaap	Operating Lease Cost OperatingLeaseCost	289000
CY2019Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	107000
CY2018Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense
	us-gaap	Operating Lease Expense OperatingLeaseExpense	231000
	us-gaap	Operating Lease Expense OperatingLeaseExpense
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1647000
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1708000
CY2018Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	142000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	19000
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	493000
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1215000
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent
	us-gaap	Operating Lease Payments OperatingLeasePayments	219000
CY2019Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	120000
CY2018Q2	us-gaap	Operating Lease Payments OperatingLeasePayments
	us-gaap	Operating Lease Payments OperatingLeasePayments
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1570000
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1573000
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset
CY2019Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0542
CY2019Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y292D
CY2019Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	236000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	262000
CY2019Q2	us-gaap	Other Assets Current OtherAssetsCurrent	168000
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	101000
CY2019Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	9000
CY2018Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	18000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-6000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	18000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-6000
CY2019Q2	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	8000000
CY2018Q2	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-250000
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	8000000
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-250000
CY2019Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	142000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	7000
CY2019Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26000
CY2018Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	100000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	50000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	124000
CY2019Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	722000
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	646000
CY2019Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	19000
CY2018Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	183000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	183000
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	352000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	384000
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3491000
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7818000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6831000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10958000
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-287362000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275638000
CY2019Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax
CY2018Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	234000
CY2019Q2	us-gaap	Share Based Compensation ShareBasedCompensation	568000
CY2018Q2	us-gaap	Share Based Compensation ShareBasedCompensation	515000
	us-gaap	Share Based Compensation ShareBasedCompensation	1230000
	us-gaap	Share Based Compensation ShareBasedCompensation	2743000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	80000000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	80000000
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.023
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0239
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.839
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30744000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3257000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.36
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	47000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	130000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1789000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.14
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4489000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6078000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.11
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.83
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5654000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.87
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.11
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	4.23
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.59
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.93
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y328D
CY2019Q2	us-gaap	Short Term Investments ShortTermInvestments	8477000
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	440000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	23000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	19000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	183000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	33756000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	14081000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	10202000
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	16887000
CY2019Q2	us-gaap	Time Deposits At Carrying Value TimeDepositsAtCarryingValue	8477000
CY2018Q4	us-gaap	Time Deposits At Carrying Value TimeDepositsAtCarryingValue	440000
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top"><td style="width: 0.5in"></td> <td style="width: 0.25in"><div style="display: inline; color: #010000">(c)</div></td> <td style="text-align: justify">Significant accounting policies, estimates and judgments:</td> </tr> </table> <div style=" margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"> </div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>there have been <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> changes to our significant accounting policies as described in our Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K for the fiscal year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>except as described below for Lease accounting.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in"> </div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">The preparation of the condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The condensed consolidated interim financial statements include estimates, which, by their nature, are uncertain.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in"> </div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">The impacts of such estimates are pervasive throughout the condensed consolidated interim financial statements and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>require accounting adjustments based on future occurrences.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in"> </div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.</div></div></div></div></div>
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46474000
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33950000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43178000

Files In Submission

Name	View Source	Status
0001171843-19-005214-index-headers.html	Edgar Link	pending
0001171843-19-005214-index.html	Edgar Link	pending
0001171843-19-005214.txt	Edgar Link	pending
0001171843-19-005214-xbrl.zip	Edgar Link	pending
apto-20190630.xml	Edgar Link	completed
apto-20190630.xsd	Edgar Link	pending
apto-20190630_cal.xml	Edgar Link	unprocessable
apto-20190630_def.xml	Edgar Link	unprocessable
apto-20190630_lab.xml	Edgar Link	unprocessable
apto-20190630_pre.xml	Edgar Link	unprocessable
exh_104.htm	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
exh_322.htm	Edgar Link	pending
f10q_080619p.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
logo.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APTO
Aptose Biosciences Inc. Stock $apto

2019 Q3 Form 10-Q Financial Statement

#000117184319005214 Filed on August 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APTO Aptose Biosciences Inc. Stock $apto

2019 Q3 Form 10-Q Financial Statement

#000117184319005214 Filed on August 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APTO
Aptose Biosciences Inc. Stock $apto